Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As that is true, and the FDA process has improved it is still murky.
There will always be scenarios where exceptions exist.
Potiga's main problem back than, and disconnect was the side effect profile: neuro-psychiatric symptoms, including confusion, hallucinations and psychotic symptoms, suicidal ideations.
This was not a concern too the the FDA advisory board, they felt the data was transient and not lingering beyond 7days and was dose dependant.
In this case, the FDA panel wasnted more data, and it was subsequently approved.
either way, there are no sure bets when involving speculative trading!
gl
ECYT: good day, and fresh start for a stock that has tested my patience, over and over.....
fresh start: timing is everything!......lol
gl
Yelp: seems like we are at the crossroads, and lets hope we break through some resistance....
should be interesting!
gl
IMUC: strong work too those who picked up on the dip and early consolidation.
gl
IMUC: impresssive day, and better than expected.
the ask is is getting hit pretty consistantly.
enjoyable first 30 minutes!
gl
strong momentum, lets hope it can continue a positive note.
this is more of a long term investmant, but look forward upcoming updates and conferences next week.
gl
ok....?!?
gl
how did you calculate that interpretation?
just curious...lol
the only thing holding this back is the companys' lack of clarity on future revenue, which may be difficult to asses at this point considering there compeitor locked up 5 year EPO - contracts with fresnius and davita.
gl
(another catalyst)
Monday, March 14th 2012
CEO, Manish Singh will be presenting at the ROTH Conference in Dana Point - California on Wednesday, March 14, 2012 from 12pm to 12:30pm PST. Click Here to register and view the webcast.
http://www.imuc.com/webcasts-and-presentations
everyone should listen to the webcasts, from prior days, and listen too the march 14 webcast thereafter.
enjoy
gl
as expected profit taking from an incredible run during the last month.
the chart and late volume action looked impressive as people profited, and people entered back into the stock. this showed confidence and positive public sentiment.
I dont think anyone can or should tell you what the daily grind is going to look like, but the intermediate and long term outlook looks great for this stock. (based on the data, and discussions by the company).
gl all, and i did add this morning.
will be watching this one from the sidelines.....
gl everyone
tough road in the "short term", but you never know.
but a great technical trade, which was ineveitable.
gl
nice bounce play for those who bought recent support levels.
good volume to support solid trades.
gl
soon to be big three, sorry boston......
http://www.theregister.co.uk/2012/03/07/wd_hitachi_gst_ftc/
gl
I'm digging the devloping chart.
and solid company too:)
gl
Transcend, is another peiece of the puzzle is added. Nuance bought out a company that could have been its competition in the healthcare market few years down the road.
nice asset, by subtraction for the long term growth.
gl
IMUC has been banging its head against $2.90 for the last 2 hours.
nice early morning support.
gl
i thought i was reading beauwolf for a second....lol
eloquent quote..
your going to see an interesting trend over the next 6 months or more....MHO
when the market weakens and institutions unload, and they increase there cash reserves, speculative plays will become the "fad" of the moment like it was in late early 2009.
in this enviroment, you will see more volume and volatility in the small caps, biotecs and speculatrive pharma plays.
companies like IMUC, AFFY, SPPI, DNDN, etc... (too name a few) will enjoy more scrutinized activity.
it maybe a lot of TLC, or Carnivorous hijinks.
gl
it showed good strength and volume in the latter day of trading.
should be an interesting show!
gl
As the current market situation dicates.
pure speculation at 13,000, built on poor fundamentals.
"there is warrant for hoping that the deflation of the exaggerated balloon of American stock values will be for the good of the world."
John Maynard Keynes
gl
lol.....your funny!
i woiuld agree if it ever gets there, but prbably would recomend taking some before that!
gl
just did, but generally i usually dont look beyond 3-6 months on my stocks, and usually re-evaluate weekly.
i'm familiar with the science, and players behind the company....the next 3 months should be exciting!
gl
lets break through one resistance level at a time....:)
gl
nice hold today.
should be some levity over the next few days.
gl
Endocyte to Resume Patient Enrollment in PROCEED Phase 3 Trial in U.S.
This is great news, as there was some concern about even getting a phase 3 study for the European approval this year. This was expressed during the last conference call/ presentation at the end of February.
Moving forward.
gl
just an interesting post to take a note of, and for lazy pontification.
George Soros Portfolio based on feb 14, 2012; 13F filing.
https://ycharts.com/topics/george_soros_portfolio
gl
thats a rumor that goes back to 2010.
gl
imteresting comment, though i think apple revenue is fixed in the current pps as the fee process nuance gets is fixed, also 40 percent of there profits are from health care, and already maximized at current levels. (JMHO)
The game changer will be the generation of revenue from Android OS.
Expectations is that Nuance will generate more revenue from mobile phones that use Google's (GOOG) Android operating system, than Apple.
Will keep an eye on for re-entry.
gl
http://www.rediff.com/money/2009/jan/24forbes-how-to-evaluate-a-companys-financial-health.htm
http://www.bizjournals.com/orlando/stories/2009/01/12/smallb5.html?page=all
http://stocks.about.com/od/evaluatingstocks/a/Fundanatools1.htm
my favorite:
http://www.investopedia.com/articles/trading/04/090904.asp#axzz1o0e9t3Yn
gl, and never that simple, and nothing beats timing!
RENN pre-market is on fire.
http://ih.advfn.com/p.php?pid=nmona&article=51454554&symbol=RENN
gl
was not very impressed with groupon, though yelp may be target for a good short. but like the long term potential.
Its going to be interesting how Goldman plays there 1.1 million shares! Its an interesting arrangement.
gl
YELP:
http://dealbook.nytimes.com/2012/03/01/yelp-prices-its-offering-at-15-a-share/
should be interesting opening.
Yelp Prices Its Offering at $15 a Share
By EVELYN M. RUSLI
Spencer Platt/Getty ImagesYelp’s market debut will be another critical test of investor appetite for technology stocks.
Yelp, the online hub for local business reviews, priced its initial public offering at $15 a share on Thursday, above its expected range, according to people briefed on the matter.
At that price, the company has raised $107.25 million, at a $898.1 million valuation. Its market debut, set for Friday morning, will be another critical test of investor appetite for technology stocks, ahead of Facebook’s multibillion-dollar I.P.O. expected later this year.
At a market value of $898.1 million. Yelp will be trading at a high multiple, at more than 10 times revenue. Still, the valuation is slightly lower than earlier estimates, reflecting concerns about the market and Yelp’s business model. The start-up, which attracts some 66 million users per month, has a huge inventory of local business pages and user-generated reviews, spanning markets in North America, Western Europe and Australia. The service is free for consumers but local businesses pay to advertise on the site and to add premium features to their Yelp pages.
In 2011, the company generated $83.3 million in revenue and a net loss attributable to common shareholders of $16.9 million.
And that’s the rub with Yelp. Founded in 2004 in San Francisco, the company is still not profitable.
In its most recent prospectus, the company acknowledged that it has “incurred significant operating losses” and warned that its revenue growth will slow as its business matures, while its costs are expected to increase. A lack of profits is far from an anomaly in the Internet sector, but Yelp is facing increasing pressure from upstarts and giants like Google. The Internet company — which has, at times, prioritized its content over Yelp’s– recently bought Zagat, another popular aggregator of reviews and business ratings. In its filing, Yelp noted that Google is its “most significant source of traffic.”
Though demand is expected to be high for Yelp’s debut, many investors are still skeptical.
“The revenues are excellent right now, but their losses are high,” said Scott Sweet, a managing partner of IPOboutique.com, an I.P.O. advisory firm. “My primary concern is the current competition and the new players that will enter this space.”
The equity markets have been choppy for technology offerings, though more stable compared to the second half of last year. On Thursday, GCT Semiconductor, a maker of wireless chips, postponed its offering.
Meanwhile, Demandware, an enterprise software business, pushed ahead with its I.P.O. plans, setting its price target at $12.50 to $14.50 per share, putting it on track to raise about $74 million at the mid-point of the range. Angie’s List, another online reviews site that went public last November, rose nearly 1 percent on Thursday to close at $16.12, about 24 percent above its offering price.
Yelp’s largest shareholders, including Jeremy Stoppelman, the company’s chief executive, will not sell any shares in the offering. The sole entity selling shares is the Yelp Foundation, the company’s nonprofit arm, which plans to sell 50,000 shares in the I.P.O. Yelp’s largest venture capital backers, Bessemer Venture Partners, Elevation Partners and Benchmark Capital Partners, own roughly 60 percent of the company, with Bessemer and Elevation each holding a 22 percent stake.
According to its prospectus, Yelp plans to use the proceeds from the I.P.O. for general expenses, including sales and marketing activities, and for acquisitions or technologies that complement its business.
Its shares will trade on the New York Stock Exchange under the ticker “YELP.”
For its offering, Yelp is selling 7.15 million shares. But its underwriters, led by Goldman Sachs, Citigroup and Jefferies, have the option to sell an additional 1.1 million shares, based on demand.
gl
the Q&A was excellent.
seems like they are confident, they will have enough supplies for the doxil (there preferred agent over the pacl). based on the need for drugs for this population to treat.
they also suggested that a smaller phase 3 study for europe would be enough and subsequent smaller cash burn.
Agree, March is going informative month.
gl
waiting for a response to a few , and figuring on how too load the IR CD to the intro-board.
as of now, not much more than whats in the companies website.
nothing new.
gl
ECYT
citigroup conference call:
http://investor.endocyte.com/events.cfm
http://www.veracast.com/citigroup/healthcare2012/events/1131_endocy/pdf/Endocyte.pdf
gl
thanks for the feed back, not expecting much from the conferences instantantly, but at the current levels (well below cash value) it will trend up for the short term, at a minimum.
the question is too what levels, is anyones guess, and will be determined by the interest, but nevertheless, go up.
thanks for the meeting report doc!
cheers
gl
will be dependant on cost control of the product with availability concerns.
first thing first would, would be approval.
over time distribution and cost control would take care of itself and will be addressed at next conference call, expected twds the end of the month of march
gl
ECYT
this is probably old news, but havent seen it on the board.
Seems like a solid entry point!
European Medical Society
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/02/human_orphan_001023.jsp&mid=WC0b01ac058001d12b&murl=menus/medicines/medicines.jsp&jsenabled=true
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/02/human_orphan_001023.jsp&mid=WC0b01ac058001d12b&murl=menus/medicines/medicines.jsp&jsenabled=true
http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2012/02/WC500123294.pdf
gl
ECYT
this is probably old news, but havent seen it on the board.
Seems like a solid entry point!
European Medical Society
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/02/human_orphan_001023.jsp&mid=WC0b01ac058001d12b&murl=menus/medicines/medicines.jsp&jsenabled=true
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2012/02/human_orphan_001023.jsp&mid=WC0b01ac058001d12b&murl=menus/medicines/medicines.jsp&jsenabled=true
http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2012/02/WC500123294.pdf
gl